All News

rare

ICYMI: Here at Last: Treatment Options for VEXAS

d Michael Putman, MD, MSCI

We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for nearly 3 years, but there has been relatively little to say about how to treat it. To date there have been over twice as many publications about VEXAS (263 publications) as there have been patients described with respect to treatment strategies (116 patients). One of the late breaking abstracts may finally have rectified this imbalance.

Read Article
uveitis eye iritis

ICYMI: Reduction of AxSpa-Associated Acute Anterior Uveitis with Certolizumab

d Meral K. El Ramahi, MD, FACP, FACR

Acute anterior uveitis is the most common extra-musculoskeletal manifestation in axial spondyloarthritis (axSpA) affecting up to 50% of patients in some age groups. AAU can have a significant impact on quality of life with risk of permanent visual deficits if not adequately treated. 

Read Article
Sleep.fatigue.doctor.jpg

CDC: Chronic Fatigue Syndrome 2021-2022

d Jack Cush, MD

The current CDC report estimates that 1.3% of adults had myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), based on the most recent population based National Health Interview Survey (NHIS 2021–2022).

Read Article
38420215_s.jpg

ICYMI: Cancer and TNF inhibitors

d Richard Conway, MBBChBAO, PhD

Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions. An oral presentation by Suarez-Almazor et al provided more supportive data on using TNFi in this population.

Read Article
kidneys

ICYMI: Urinary biomarkers precede loss of kidney function for lupus nephritis

d Eric Dein, MD

In Abstract 0850, Dr. Andrea Fava from Johns Hopkins presents research on the value of urinary biomarkers as measure of intrarenal inflammation.

Read Article
Expert consensus(ASAS) prefers SpondyloArthritis(axSpA) as preferred over "ankylosing spondylitis" (historic but no longer appropriate based on MRI research showing this is more than SI disease). AS radiographic axSpA(r-axSpA) can be used interchangeably https://t.co/jvT3lQFaPq https://t.co/WRNrbfjK1S

Links:

Dr. John Cush RheumNow ( View Tweet)
Danish study compared 106K adults w/ major osteoporotic fracture (hip, vertebrae, wrist, humerus) vs 1+ mill controls & found Mortality highest 30d following 1st index hip Fx (HR 10.98 women; & HR 16.40 men). Pneumonia most common cause of mortality https://t.co/0D7ynN4f5L https://t.co/qX61cgq1SL

Links:

Dr. John Cush RheumNow ( View Tweet)

Hemophagocytic Lymphohistiocytosis in Still's disease Dr. Bella Mehta discusses abstract 1143, presented at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/AFoKm6kT86 https://t.co/dLTjTOdbmv

Links:

Dr. John Cush RheumNow ( View Tweet)
Watch: Non-TNFi b/tsDMARDs vs. TNFi in RA-ILD https://t.co/fOz4jH58r9 https://t.co/jSHnsZscPg

Links:

Dr. John Cush RheumNow ( View Tweet)
Cardiology 101 for the Rheumatologist Dr. Janet Pope reports on a cardiology session presented a 2023 ACR Convergence in San Diego, CA https://t.co/0cS8JVneIG https://t.co/6SIPx6WmqX

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA Warning on CAR-T Cell Therapy The FDA issued a safety alert on CAR-T cell immunotherapies; noting reports of T-cell malignancies (CAR-positive lymphoma) arising in patients treated with BCMA- or CD19-directed autologous CAR T cell immunotherapies. https://t.co/1OiMWJMskz https://t.co/8i8LFMcb1s

Links:

Dr. John Cush RheumNow ( View Tweet)
Full read BMJ ovverview of PMR - PMR Clinically recognized 1957 - Is it a uniquie vs overlap entity - Is there subclinical GCA in PMR? - Is PMR for PCPs? https://t.co/0BKGdt5Kxf https://t.co/sfAZoYyVan

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: How early is early in PsA? Guidelines for the management of PsA recommend the early referral of patients with the suspected condition for early assessment and treatment. https://t.co/AAZegiV6OL https://t.co/v5jIsPjX0c

Links:

Dr. John Cush RheumNow ( View Tweet)
Subtype of dermatomyositis is positive for Melanoma differentiation-associated protein 5 (MDA5) antibody. This poor prognosis subtype has distinctive rashes, rapidly progressive interstitial lung disease, lymphopenia &elevated ferritin levels https://t.co/FJjdO27cQQ https://t.co/gis2aWOLa7

Links:

Dr. John Cush RheumNow ( View Tweet)
Early bird pricing has been extended! Register today! https://t.co/BysC0RunUh https://t.co/4Ar0kHa4tt

Links:

Dr. John Cush RheumNow ( View Tweet)
Palmoplantar pustulosis (PPP) is difficult to treat; w/ few reports of JAKi efficacy. Now a report of 21 PPP pts given bimekizumab and 17 patients showed complete clearance in 1 to 4 months. SAPHO pts had complete clearance of skin & improved joint pain https://t.co/tYpHCxFOBI https://t.co/i4o3KnGlPY

Links:

Dr. John Cush RheumNow ( View Tweet)
UK Dermatology Registry of 13 699 Psoriasis pts on biologics (25K biologic exposures) found 1% risk of paradoxical eczema. Biologics included inhibitors of TNF, IL-17, IL12/23, IL-23. Lowest risk w/ IL-23i (0.56/100kPY), and higher w/ IL-17i (1.22) https://t.co/fOX6VGJQLk https://t.co/u1p1sidCte

Links:

Dr. John Cush RheumNow ( View Tweet)
Post-Menopausal Osteoporosis Review and Recommendations A recent New England Journal review of post-menopausal osteoporosis (OP) provided updated information, strategies and a review of guidelines and clinical recommendations. https://t.co/TkJjsX98Ww https://t.co/2Hi72GjEHM

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: The Heart of Lupus Few people are aware of the EULAR recommendations1 for cardiovascular (CV) risk management in systemic lupus erythematosus (SLE) published in 2022. The recommendations had 4 overarching principles... https://t.co/5I5eYNqHIu https://t.co/W6VzUFs6kN

Links:

Dr. John Cush RheumNow ( View Tweet)
Withdraw DMARDS after remission? Considering withdrawing DMARDs after remission is on our minds. When patients inquire about tapering or stopping DMARDs while doing well, we often lack a clear-cut answer. https://t.co/wqcCff7kjx https://t.co/vq9ee1dZNX

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×